First Time Loading...

GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 705 GBX 1.91% Market Closed
Updated: May 2, 2024
Section:
 

Relative Value

The Relative Value of one GSK stock under the Base Case scenario is 2 595.26 GBX. Compared to the current market price of 1 705 GBX, GlaxoSmithKline PLC is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSK Relative Value
Base Case
2 595.26 GBX
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
22
vs Industry
49
Median 3Y
2
Median 5Y
2
Industry
2.4
Forward
2.1
More Details
14
P/E
P/E
Price to Earnings
14
vs History
24
vs Industry
33
Median 3Y
9.6
Median 5Y
12
Industry
22.9
Forward
10.5
More Details
10.2
P/OCF
P/OCF
Price to OCF
10.2
vs History
16
vs Industry
36
Median 3Y
7.7
Median 5Y
7.7
Industry
17.1
More Details
58.3
P/FCFE
P/FCFE
Price to FCFE
58.3
vs History
16
vs Industry
11
Median 3Y
28.7
Median 5Y
18.4
Industry
23.2
More Details
5.2
P/B
P/B
Price to Book Value
5.2
vs History
35
vs Industry
13
Median 3Y
4.4
Median 5Y
4.7
Industry
2.1
More Details
2.6
EV/S
EV/S
Enterprise Value to Sales
2.6
vs History
38
vs Industry
43
Median 3Y
2.3
Median 5Y
2.5
Industry
2.6
Forward
2.4
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
51
vs Industry
54
Median 3Y
3.4
Median 5Y
3.6
Industry
5.1
More Details
7.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.5
vs History
50
vs Industry
42
Median 3Y
6.9
Median 5Y
7.5
Industry
13.6
Forward
7.3
More Details
9.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
9.5
vs History
64
vs Industry
39
Median 3Y
9.3
Median 5Y
9.8
Industry
17
Forward
8.8
More Details
11.7
EV/OCF
EV/OCF
Enterprise Value to OCF
11.7
vs History
19
vs Industry
34
Median 3Y
9.6
Median 5Y
10.1
Industry
15.8
More Details
17.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.9
vs History
20
vs Industry
23
Median 3Y
15.2
Median 5Y
14.1
Industry
17.6
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
1
vs Industry
36
Median 3Y
1.7
Median 5Y
1.5
Industry
1.9
More Details

Multiples Across Competitors

GSK Competitors Multiples
GlaxoSmithKline PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
GlaxoSmithKline PLC
LSE:GSK
69.2B GBP 2.3 14 7.5 9.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
736B USD 21.6 140.7 63.4 72.8
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 17.1 47.6 34.8 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
363B USD 4.4 9 11.9 15.8
US
Merck & Co Inc
NYSE:MRK
326.6B USD 5.4 894.7 44.5 86.9
UK
AstraZeneca PLC
LSE:AZN
188.7B GBP 5.1 39.6 140.8 225.8
CH
Novartis AG
SIX:NOVN
182B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
175.9B CHF 3 15.3 8.7 10.3

See Also

Summary
GSK intrinsic value, competitors valuation, and company profile.
DCF Valuation
GSK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GSK stock valuation using valuation multiples.
Wall Street Estimates
GSK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GSK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.